News | December 21, 2024
Merck closes license agreement for LM-299
Merck will record a pre-tax charge relating to the upfront payment of $588 million
Merck will record a pre-tax charge relating to the upfront payment of $588 million
An investigational long-acting monoclonal antibody designed to protect infants from RSV disease during their first RSV season
Merck has also decided to end the favezelimab clinical development program
Acquisition adds potential best-in-class disease-modifying therapy for Alzheimer's disease
Based on data, 1.75 mg/kg dose established as recommended dose for Phase 3 trial of this investigational antibody-drug conjugate
For people with relapsed or refractory diffuse large B-cell lymphoma
The first and only immuno-oncology drug approved for the treatment of nasopharyngeal carcinoma
GFP is a common fusion protein tag that enables protein expression to be monitored, quantified, and localized within the complex environment of the cell
ISB 2001 demonstrated a favorable safety and tolerability profile, and an overall response rate (ORR) of 75% in r/r MM
Commercial license to Synaffix technologies follows a series of successful initial preclinical proof of concept studies
Subscribe To Our Newsletter & Stay Updated
